Literature DB >> 18334899

Simultaneous subacute coronary drug-eluting stent thrombosis in two different vessels of a patient with factor V Leiden mutation.

Parham Eshtehardi1, Masoud Eslami, Davood Akhlagh Moayed.   

Abstract

We review the case of a 46-year-old man who underwent elective percutaneous coronary intervention and stenting of the left anterior descending artery and right coronary artery with two sirolimus- and paclitaxel-eluting stents. Four days after angioplasty, he was readmitted with cardiogenic shock due to acute anterior and inferior myocardial infarction. Coronary angiography revealed subacute thrombosis of both stents, and balloon dilation was performed successfully thereafter. The follow-up investigations revealed that the patient was a carrier of factor V Leiden. We hereby discuss the importance of factor V Leiden as the most common cause of hypercoagulable state and its probable role in acute and subacute coronary stent thrombosis in drug-eluting stents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18334899     DOI: 10.2459/JCM.0b013e3282eee98b

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  3 in total

1.  A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty.

Authors:  M Silvano; C F Zambon; G De Rosa; M Plebani; V Pengo; M Napodano; R Padrini
Journal:  J Thromb Thrombolysis       Date:  2011-02       Impact factor: 2.300

2.  Acute promyelocytic leukemia as a cause of intracoronary drug-eluting-stent thrombosis.

Authors:  Zaven Sargsyan; Christopher Higgins; Sanda Alexandrescu; David A Ott; Surendra K Jain
Journal:  Tex Heart Inst J       Date:  2012

3.  New perspectives on treatment strategies for patient with acute myeloid leukemia and complex karyotype abnormalities after percutaneous coronary intervention: A case report.

Authors:  Jie Wang; Rong Chen; Xiaoqi Lin; Yubo Wang; Jian-Hua Wang; Yun Wu
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.